In vivo testing of three antigen-targeted CAR T cells against glioblastomas (HER2, IL13Ra2, EphA2) [165,166] led to successful antitumor responses against almost 100% of the tumour cells from patient-derived glioblastoma cell lines [166]. This evidence concerns the gene ERBB2 and glioblastoma.